Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 1.83 B

Soleno Therapeutics, Inc. Market Capitalization is USD 1.83 B on January 14, 2025, a 9.39% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Soleno Therapeutics, Inc. 52-week high Market Capitalization is USD 2.55 B on November 11, 2024, which is 39.17% above the current Market Capitalization.
Soleno Therapeutics, Inc. 52-week low Market Capitalization is USD 1.48 B on April 12, 2024, which is -19.43% below the current Market Capitalization.
Soleno Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 1.94 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years